Full Press Release Details
LOS ANGELES , Sept. 5, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (" Armata " or the " Company "), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx , M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024 .
Armata's presentation is scheduled for Wednesday, September 11 , from 8:00-8:30 AM ET .
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa , Staphylococcus aureus , and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Media Contacts:
At Armata: Pierre Kyme Armata Pharmaceuticals, Inc. [email protected] 310-665-2928 x234
Investor Relations: Joyce Allaire LifeSci Advisors, LLC [email protected] 212-915-2569
SOURCE Armata Pharmaceuticals, Inc.